Article

Mount Sinai Launches Institute for Airway Sciences

Author(s):

The newest venture from Mount Sinai is intended to build a pipeline of physician-scientists.

This week, Mount Sinai Health System and Icahn School of Medicine announced the launch of the Institute for Airway Sciences (IAS), a multidisciplinary institute intended to establish new therapies for patients with sinus, laryngotracheal airway, and lung diseases.

The institute is the first clinical and research collaborative of its kind in the US.

Under the guidance of Eric Genden, MD, MBA, Professor and System Chair of Otalaryngology, along with several clinical directors at Mount Sinai including Dr. Isidore Friesner and Dr. Charles Powell, the Institute for Airway Sciences will bring together a multidisciplinary group of researchers and clinicians to establish new goals for conquering airway diseases.

The institute will aid in the promotion of research and innovation of 4 resource cores including the Black Family Stem Cell Institute, the Department of Cell, Developmental and Regenerative Biology, the Division of Pulmonary, Critical Care and Sleep Medicine, and the Department of Otolaryngology – Head and Neck Surgery.

To encourage innovative projects from medical students and residents in training as well as to build a pipeline of physician-scientists, the IAS will award pilot grants and user scholarships in addition to offering seminars and research-in-progress talks focused on airway science and various diseases that affect the airway.

“We wanted to develop a clinical and research hub solely dedicated to the airway—from the sinuses all the way down to the lungs,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn Mount Sinai and President for Academic Affairs of the Mount Sinai Health System. “The researchers and clinicians involved in this collaboration bring profound expertise and talent in their respective areas and we look forward to bringing the Institute’s mission and vision to life.”

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
Discussing Use of Vaping Among Students, Conversations About Vaccines
© 2024 MJH Life Sciences

All rights reserved.